biodeep.ai is BioFund's cell engineering and biosimilar development platform — built to take complex molecules from sequence to validated cell line, across therapeutic modalities and disease areas.
Getting a complex molecule from sequence to a stable, documented, production-ready cell line is where most programmes lose time, money, and momentum. The technical barriers — expression yield, stability, glycosylation, manufacturability — are the same whether the target is a biosimilar, a rare disease therapeutic, or an emerging modality nobody has expressed cleanly before.
biodeep.ai was built to solve exactly that problem — from the inside, driven by our own research needs. That infrastructure is now available to a small number of partners facing the same challenges.
An operationally validated Master Cell Line Bank spanning biosimilar programmes, rare disease therapeutics, and emerging modalities — with mechanistic breadth across checkpoint inhibitors, TNF-α inhibition, rare disease enzymes, antimicrobials, and diagnostic platforms. Each line is fully validated, built to late-stage development standards, and engineered to support the full arc from discovery through manufacturing transfer. The platform's capabilities extend across diverse therapeutic areas and disease domains.
End-to-end cell line creation for research-use and therapeutic biosimilar programmes. From sequence to stable, high-yield expression — with the complete data package to support third-party validation, academic collaboration, and regulatory submission. Cell lines established early in development de-risk manufacturability at scale and enable consistent, reliable production from the start.
AI-assisted target identification and de novo protein design for novel oncology therapeutics — optimizing for binding affinity, stability, manufacturability, and off-target risk mitigation. High-confidence candidates are generated computationally before a single experiment runs, eliminating traditional discovery bottlenecks and compressing the path to translational validation.
Companion animals naturally develop diseases that mirror human pathology — making them powerful translational models across therapeutic areas. This parallel approach simultaneously generates human-relevant regulatory data and species-specific clinical evidence, de-risking both pathways and building richer, more credible data packages than single-species programmes.
Every asset in the bank is built to perform consistently across laboratories, institutions, and regulatory contexts. Reproducibility is the baseline from which everything else follows.
Every cell line is documented to late-stage development standards from day one — the definition of complete on this platform.
Every programme is built to translate — across species, regulatory contexts, and the full arc from early discovery to submission-ready data. Parallel validation is built in from the start. It is how the work is structured.
biodeep.ai was built because we faced these problems ourselves.
Getting a complex molecule expressed at stable, high yield. Building a validated cell line that holds through the full development arc. Bridging the gap between an academic discovery and a data package that survives regulatory scrutiny. Building a biosimilar programme and still searching for the cell engineering infrastructure to build it on.
We respond only where there is genuine scientific alignment.